or invariant NK (iNK) cells, but typical PSC-to-iNK cell differentiation protocols are inconsistent and lack scalability. Using a suspension medium with 3D PSC expansion capabilities, scientists ...

Cellistic has launched the Echo-NK platform to enable the scalable manufacturing of allogeneic cell therapies to target multiple diseases.

Technological advances empower the modification of NK cells and renewed potential for therapeutic uses in cancer and autoimmunity.

We have dedicated cleanrooms for induced pluripotent stem cells (iPSC), mesenchymal stromal cells (MSC), chimeric antigen receptor T-cells (CAR-T), T-cell receptor-engineered T-cells (TCR-T), natural ...